AQST - Aquestive Therapeutics, Inc.
IEX Last Trade
3.54
0.020 0.565%
Share volume: 26,571
Last Updated: Fri 27 Dec 2024 08:30:11 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$3.52
0.02
0.57%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-02 | 2022-11-01 | 2023-03-31 | 2023-05-02 | 2023-08-07 | 2023-11-06 | 2024-03-05 | 2024-05-07 | |
| Assets | |||||||||
| Total Assets | 56.310 M | 51.845 M | 57.070 M | 61.285 M | 56.994 M | 59.448 M | 57.418 M | 129.523 M | |
| Current Assets | 43.505 M | 38.087 M | 39.888 M | 43.706 M | 39.788 M | 42.457 M | 40.966 M | 113.379 M | |
| Inventories | 5.008 M | 6.725 M | 5.780 M | 6.981 M | 5.950 M | 7.079 M | 6.769 M | 7.734 M | |
| Other Current Assets | 1.637 M | 1.976 M | 2.131 M | 2.292 M | 1.301 M | 1.911 M | 1.854 M | 2.121 M | |
| Short Term Investments | 1.637 M | 1.976 M | 2.131 M | 2.292 M | 1.301 M | 1.911 M | 1.854 M | 2.121 M | |
| Total Receivables | 19.165 M | 10.737 M | 4.704 M | 7.551 M | 10.101 M | 8.550 M | 8.471 M | 8.324 M | |
| Current Cash | 17.695 M | 18.649 M | 27.273 M | 26.882 M | 22.436 M | 24.917 M | 23.872 M | 95.200 M | |
| Total Non-current Assets | 12.805 M | 13.758 M | 17.182 M | 17.579 M | 17.206 M | 16.991 M | 16.452 M | 16.144 M | |
| Property Plant Equipment | 4.569 M | 4.284 M | 4.085 M | 3.814 M | 4.602 M | 4.551 M | 4.179 M | 4.046 M | |
| Other Assets | 8.211 M | 7.987 M | 11.662 M | 12.369 M | 11.247 M | 11.123 M | 10.995 M | 10.859 M | |
| Intangible Assets | 25.000 K | 1.487 M | 1.435 M | 1.396 M | 1.357 M | 1.317 M | 1.278 M | 1.239 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 56.310 M | 51.845 M | 57.070 M | 61.285 M | 56.994 M | 59.448 M | 57.418 M | 129.523 M | |
| Total liabilities | 152.667 M | 159.664 M | 175.624 M | 170.520 M | 163.645 M | 162.375 M | 163.905 M | 165.824 M | |
| Total current liabilities | 29.636 M | 36.560 M | 39.528 M | 40.383 M | 38.653 M | 24.057 M | 18.308 M | 18.058 M | |
| Accounts Payable | 8.887 M | 11.072 M | 9.946 M | 12.440 M | 10.689 M | 9.994 M | 8.926 M | 10.523 M | |
| Other liabilities | 77.708 M | 83.089 M | 97.563 M | 99.235 M | 98.581 M | 98.254 M | 112.690 M | 113.723 M | |
| Current long term debt | 10.663 M | 15.071 M | 18.955 M | 17.523 M | 18.709 M | 4.973 M | 412.000 K | 437.000 K | |
| Long term debt | 45.323 M | 40.015 M | 38.533 M | 30.902 M | 26.411 M | 40.064 M | 32.907 M | 34.043 M | |
| Other liabilities | 77.708 M | 83.089 M | 97.563 M | 99.235 M | 98.581 M | 98.254 M | 112.690 M | 113.723 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -96.357 M | -107.819 M | -118.554 M | -109.235 M | -106.651 M | -102.927 M | -106.487 M | -36.301 M | |
| Common stock | 45.463 M | 53.425 M | 54.584 M | 55.632 M | 57.351 M | 64.679 M | 67.362 M | 73.615 M | |
| Retained earnings | -286.318 M | -298.855 M | -311.207 M | -303.139 M | -308.931 M | -310.966 M | -319.077 M | -331.905 M |